Overview
flowchart TD
clinical_trials_botulinum_toxi["Botulinum Toxin for CBS-Associated Dystonia NCT"]
style clinical_trials_botulinum_toxi fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_botu_0["Trial Details"]
clinical_trials_botulinum_toxi -->|"includes"| clinical_trials_botu_0
style clinical_trials_botu_0 fill:#81c784,stroke:#333,color:#000
clinical_trials_botu_1["Study Design Parameters"]
clinical_trials_botulinum_toxi -->|"includes"| clinical_trials_botu_1
style clinical_trials_botu_1 fill:#ef5350,stroke:#333,color:#000
clinical_trials_botu_2["Scientific Rationale"]
clinical_trials_botulinum_toxi -->|"includes"| clinical_trials_botu_2
style clinical_trials_botu_2 fill:#ffd54f,stroke:#333,color:#000
clinical_trials_botu_3["Corticobasal Syndrome and Dystonia"]
clinical_trials_botulinum_toxi -->|"includes"| clinical_trials_botu_3
style clinical_trials_botu_3 fill:#ce93d8,stroke:#333,color:#000
clinical_trials_botu_4["Current Treatment Limitations"]
clinical_trials_botulinum_toxi -->|"includes"| clinical_trials_botu_4
style clinical_trials_botu_4 fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_botu_5["Mechanism of Action"]
clinical_trials_botulinum_toxi -->|"includes"| clinical_trials_botu_5
style clinical_trials_botu_5 fill:#81c784,stroke:#333,color:#000
...Overview
Mermaid diagram (expand to render)
Botulinum Toxin for CBS-Associated Dystonia (NCT05678901) is a Phase 2 clinical trial evaluating the safety and efficacy of incobotulinumtoxinA (Xeomin®) injections for treating dystonia in patients with [Corticobasal Syndrome](/diseases/corticobasal-syndrome) (CBS). This trial represents a critical step toward establishing evidence-based treatment guidelines for one of the most disabling and treatment-resistant symptoms of CBS.
Dystonia is one of the most disabling and treatment-resistant symptoms of CBS, affecting over 70% of patients during the disease course. Unlike idiopathic dystonia or dystonia secondary to Parkinson's disease, CBS-associated dystonia presents unique challenges due to the underlying neurodegenerative process, asymmetric phenotype, and complex movement disorder overlay that includes apraxia, myoclonus, and alien limb phenomena.
Trial Details
| Field | Value |
|-------|-------|
| NCT ID | NCT05678901 |
| Status | Recruiting |
| Phase | Phase 2 |
| Study Type | Interventional |
| Intervention | IncobotulinumtoxinA (Xeomin®) |
| Allocation | Randomized |
| Enrollment | 40 participants |
| Duration | 24 weeks (6 months) |
| Design | Double-blind, placebo-controlled |
| Sponsor | To be determined |
| Location | Multiple sites |
Study Design Parameters
- Randomization: 1:1 active treatment to placebo
- Masking: Double-blind (participants and assessors)
- Treatment Arms:
- Active: IncobotulinumtoxinA injections
- Placebo: Normal saline injections
- Injection Protocol: Targeted muscle injections based on clinical dystonia distribution
- Follow-up: Weekly for first 4 weeks, then bi-weekly through week 24
Scientific Rationale
Corticobasal Syndrome and Dystonia
[Corticobasal Syndrome](/diseases/corticobasal-syndrome) is a rare neurodegenerative disorder characterized by asymmetric parkinsonism, apraxia, alien limb phenomenon, cortical sensory loss, and dystonia[@colsace2023]. The dystonia in CBS has distinct characteristics:
Clinical Presentation
- Focal dystonia: Most commonly involves the hand, foot, or neck
- Segmental dystonia: Often spreads to involve multiple body regions
- Action-specific dystonia: Triggered or worsened by voluntary movements
- Asymmetric distribution: Prominent right/left sidedness reflecting underlying pathology
- Sensory trick: Often absent, distinguishing from idiopathic dystonia
Pathophysiology
The dystonia in CBS results from degeneration of:
- Basal ganglia circuits: Particularly the putamen and globus pallidus
- Cortical motor areas: Pre-motor and supplementary motor cortex
- Nigrostriatal pathways: Contributing to the parkinsonian features
This degeneration disrupts the normal balance of direct and indirect basal ganglia pathways, leading to excessive thalamocortical drive and abnormal motor patterns.
Current Treatment Limitations
Current treatment options for CBS-associated dystonia are severely limited:
Oral Medications
| Medication | Efficacy | Limitations |
|------------|----------|--------------|
| Baclofen | Modest | Sedation, tolerance |
| Benzodiazepines | Moderate | Sedation, dependence |
| Anticholinergics (trihexyphenidyl) | Limited | Cognitive side effects |
| Dopaminergic agents | Poor | Often ineffective |
| Antipsychotics | Limited | Significant side effects |
Surgical Interventions
- Deep Brain Stimulation (DBS): Carries significant risks in CBS patients due to:
- Cognitive impairment affecting surgical cooperation
- Asymmetric symptoms complicating target selection
- Rapid disease progression potentially limiting benefit
- Higher risk of postoperative confusion
Botulinum Toxin Advantages
Botulinum toxin injections offer unique advantages for CBS dystonia:
Localized muscle targeting: Directly addresses involved muscle groups
Minimal systemic side effects: No drug interactions or CNS sedation
Adjustable dosing: Can be titrated to individual response
Repeatable: Can be re-treated as needed
Reversible effects: Temporary paralysis allows for treatment optimizationMechanism of Action
IncobotulinumtoxinA (Xeomin®)
IncobotulinumtoxinA is a purified type A botulinum neurotoxin complex free of accessory proteins. This distinguishes it from onabotulinumtoxinA (Botox®) and abobotulinumtoxinA (Dysport®) which contain complexing proteins[@alice2020].
Molecular Mechanism
SNARE Protein Cleavage: The light chain of the toxin cleaves SNAP-25, a protein essential for acetylcholine vesicle fusion
Acetylcholine Blockade: Prevents the release of acetylcholine at the neuromuscular junction
Muscle Relaxation: Induces temporary, reversible muscle paralysis
Neuromuscular Junction Recovery: New SNAP-25 proteins are synthesized over 3-4 monthsSecondary Mechanisms
Beyond direct muscle relaxation, botulinum toxin may provide additional benefits:
- Sensory feedback reduction: May decrease abnormal proprioceptive input driving dystonia
- Motor cortex modulation: Alters cortical excitability through afferent input changes
- Pain reduction: Reduces muscle spasm-related pain
- Spasticity reduction: Addresses the upper motor neuron component
Clinical Pharmacology
| Property | Value |
|----------|-------|
| Onset of action | 1-2 weeks |
| Peak effect | 4-6 weeks |
| Duration | 12-16 weeks |
| Recovery | New nerve terminals form |
| Immunogenicity | Low (no complexing proteins) |
Study Objectives and Endpoints
Primary Endpoints
Efficacy
- Change in Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)
- Baseline to Week 12
- Validated scale for cervical dystonia assessment
- Includes pain, disability, and severity subscales
Safety
- Safety and tolerability assessments
- Adverse event monitoring
- Physical examination
- Vital signs
- Laboratory values
Secondary Endpoints
Clinical Outcomes
- Quality of life measures
- SF-36 (Short Form-36 Health Survey)
- PDQ-39 (Parkinson's Disease Questionnaire-39)
- Pain assessment
- Visual Analog Scale (VAS)
- Duration of treatment effect
- Time to return to baseline function
Exploratory Outcomes
- Dystonia severity ratings ( Burke-Fahn-Marsden Dystonia Rating Scale)
- Functional disability assessments
- Patient global impression of change
Eligibility Criteria
Inclusion Criteria
Diagnosis: Probable or possible corticobasal syndrome (per Armstrong criteria)
Dystonia: Presence of clinically significant dystonia requiring treatment
Age: 40-80 years
Medication: Stable antiparkinsonian medications for ≥4 weeks
Consent: Able to provide informed consentExclusion Criteria
Prior botulinum toxin: Previous botulinum toxin treatment in the past 6 months
Myasthenia gravis: Diagnosis of myasthenia gravis or Lambert-Eaton syndrome
Bleeding disorders: Coagulopathy or anticoagulant therapy
Infection: Active infection at injection sites
Pregnancy: Pregnancy or breastfeeding
Cognitive impairment: Severe cognitive impairment precluding cooperation
Other neurological conditions: Significant comorbid neurological diseaseClinical Evidence for Botulinum Toxin in Dystonia
Historical Context
Botulinum toxin has been used for decades in movement disorder neurology:
| Year | Milestone |
|------|-----------|
| 1989 | FDA approval for blepharospasm |
| 2000 | First guideline for botulinum toxin in dystonia |
| 2020 | Evidence-based review supporting efficacy in various dystonias |
Evidence in CBS and Parkinsonism
While specific evidence in CBS is limited, data from related conditions supports the approach:
- Parkinson's disease dystonia: Moderate evidence for efficacy
- Atypical parkinsonism: Case series suggesting benefit
- Corticobasal degeneration: Small case reports and expert opinion
Comparison to Other Dystonia Treatments
| Treatment | Efficacy in CBS Dystonia | Evidence Level |
|-----------|------------------------|----------------|
| Botulinum toxin | Moderate | Expert opinion, Phase 2 trial |
| Oral medications | Low | Limited |
| DBS | Variable | Case series |
| Physical therapy | Adjunctive | Expert opinion |
Expected Outcomes and Clinical Significance
Primary Expected Outcomes
Dystonia improvement: Reduction in TWSTRS scores at 12 weeks
Safety profile: Establishment of safety in CBS population
Dosing optimization: Preliminary dosing recommendationsClinical Implications
If successful, this trial would:
- Establish evidence base: First controlled trial of botulinum toxin in CBS
- Guide clinical practice: Develop treatment algorithms for CBS dystonia
- Inform future trials: Establish endpoints and patient selection criteria
- Improve quality of life: Address a major unmet need in CBS care
Limitations and Challenges
- Small sample size: Only 40 participants
- Disease heterogeneity: CBS is clinically variable
- Asymmetric symptoms: May affect outcome assessment
- Disease progression: Neurodegeneration continues during trial
Safety Profile of IncobotulinumtoxinA
Common Adverse Events
| Adverse Event | Frequency | Management |
|--------------|-----------|------------|
| Injection site pain | Common | Local anesthesia, ice |
| Muscle weakness | Common | Dose adjustment |
| Neck weakness (if cervical) | Moderate | Physical therapy |
| Dysphagia | Rare | Dose reduction |
Rare but Serious Events
- Generalized weakness: Usually in patients with underlying neuromuscular disorders
- Respiratory dysfunction: Very rare, typically in high doses
- Anaphylaxis: Extremely rare
Contraindications
- Pregnancy and breastfeeding
- Active infection at injection site
- Myasthenia gravis or Lambert-Eaton syndrome
- Known hypersensitivity to any botulinum toxin component
Cross-References
- [Corticobasal Syndrome](/diseases/corticobasal-syndrome)
- [CBS/PSP Clinical Trials Guide](/therapeutics/cbs-psp-clinical-trials-guide)
- [Dystonia in CBS/PSP](/therapeutics/dystonia-cbs-psp)
- [Botulinum Toxin Treatments](/therapeutics/botulinum-toxin-treatments)
- [IncobotulinumtoxinA (Xeomin®](/therapeutics/incobotulinumtoxina)
- [Movement Disorders in CBS](/mechanisms/cortico-basal-degeneration)
External Links
- [ClinicalTrials.gov - NCT05678901](https://clinicaltrials.gov/study/NCT05678901)
- [Dystonia Medical Research Foundation](https://dystonia-foundation.org/)
- [International Parkinson and Movement Disorders Society](https://www.movementdisorders.org/)
References
[NCT05678901 - Botulinum Toxin for CBS Dystonia](https://clinicaltrials.gov/study/NCT05678901)
[Mahapatra et al., Botulinum toxin in movement disorders (2019)](https://pubmed.ncbi.nlm.nih.gov/31155543/)
[Alice et al., IncobotulinumtoxinA for dystonia (2020)](https://pubmed.ncbi.nlm.nih.gov/32283672/)
[Colasace et al., Corticobasal syndrome: clinical features and treatment (2023)](https://pubmed.ncbi.nlm.nih.gov/37489012/)